Literature DB >> 18660944

Peak VO2 and VE/VCO2 slope in betablockers era in patients with heart failure: a Brazilian experience.

Guilherme Veiga Guimarães1, Mário Sérgio Vaz da Silva, Veridiana Moraes d'Avila, Silvia Moreira Ayub Ferreira, Christiano Pereira Silva, Edimar Alcides Bocchi.   

Abstract

BACKGROUND: Studies have demonstrated that peak oxygen consumption (peak VO2) and the VE/VCO2 slope are predictors of survival in patients with heart failure (HF). However, with the advent of betablockers in the treatment of HF, the prognostic values of peak VO2 and VE/VCO2 slope have not been fully established.
OBJECTIVE: To evaluate the effect of betablocker use on the prognostic value of peak VO2 and VE/VCO2 slope in patients with HF.
METHODS: We studied 391 patients with heart failure, aged 49 +/- 14 years and presenting a left ventricular ejection fraction of 38 +/- 10%. The total number of patients that used (Group I - GI) or did not use (Group II - GII) betablockers was 229 and 162, respectively. All patients were submitted to a cardiopulmonary stress test on a treadmill, using the Naughton protocol.
RESULTS: A peak VO2 < or = 10 ml x kg(-1) x min(-1) identified high-risk patients, whereas values > 16 ml x kg(-1) min(-1) categorizes patients with a better mid-term prognosis. Peak VO2 values between > 10 and < or = 16 ml x kg(-1) x min(-1) indicated moderate risk for cardiac event in four years of follow up. The betablocker use significantly reduced the VE/VCO2 slope in patients with HF. The prognostic value of the VE/VCO2 slope < 34 in the group using betablocker can reflect the impact of the drug on this cardiorespiratory variable.
CONCLUSION: A low peak VO2 and an elevated VE/VCO2 slope are strong and independent predictors of cardiac events in HF. Thus, both variables remain important survival predictors in patients with HF, especially at the age of betablockers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18660944     DOI: 10.1590/s0066-782x2008001300007

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


  4 in total

1.  Metabolic parameters derived from cardiopulmonary stress testing for prediction of prognosis in patients with heart failure: the ochsner experience.

Authors:  Joaquin Crespo; Carl J Lavie; Richard V Milani; Yvonne E Gilliland; Hamang M Patel; Hector O Ventura
Journal:  Ochsner J       Date:  2009

2.  Atrial fibrillation in heart failure with reduced ejection fraction: a case report of exercise training.

Authors:  Guilherme Veiga Guimarães; Jean Marcelo Roque; Alexander D T Machado; Miguel Morita Fernandes-Silva; Paul Roberto Chizzola; Edimar Alcides Bocchi
Journal:  Eur Heart J Case Rep       Date:  2020-10-15

Review 3.  Stratification of the risk of sudden death in nonischemic heart failure.

Authors:  Maurício Pimentel; Leandro Ioschpe Zimerman; Luis Eduardo Rohde
Journal:  Arq Bras Cardiol       Date:  2014-08-29       Impact factor: 2.000

4.  Low Concordance between NYHA Classification and Cardiopulmonary Exercise Test Variables in Patients with Heart Failure and Reduced Ejection Fraction.

Authors:  Luiz Eduardo Fonteles Ritt; Rebeca Sadigursky Ribeiro; Isabela Pilar Moraes Alves de Souza; João Victor Santos Pereira Ramos; Daniel Sadigursky Ribeiro; Gustavo Freitas Feitosa; Queila Borges de Oliveira; Ricardo Stein; Eduardo Sahade Darzé
Journal:  Arq Bras Cardiol       Date:  2022-04-04       Impact factor: 2.667

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.